Category:

Using Pharmacogenomics to Better Understand the Role of Selected Medications and Birth Defect Risk

DNA encased in a pill with a pregnant woman

Through a funding opportunity from CDC’s Office of Genomics and Precision Public Health in collaboration with the Office of Advanced Molecular Detection, CDC’s Birth Defects Monitoring and Research Branch in the National Center on Birth Defects and Developmental Disabilities will conduct a 2-year project to gather genome-wide genotyping data to look at relationships between pharmacogenomic Read More >

April 12, 2022 by Mary Jenkins, Lynn Almli, Jennita Reefhuis. Division of Birth Defects and Infant Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia

genomics, pharmacogenomics

Tracking the Scientific Literature on the Impact of Pharmacogenomics on Clinical Practice and Public Health

bar graph of Trends in pharmacogenomic implementation studies, 2012-2021

Pharmacogenomics (PGx) is an emerging field that investigates genetic differences in drug effectiveness and safety. PGx is an essential component of precision medicine and seeks to provide the right medication for the right person at the right time. Advances in PGx promise to improve treatment of many diseases such as cancer and cardiovascular disease. In Read More >

April 4, 2022 by Sarina Abrishamcar, Emory University Rollins School of Public Health, W. David Dotson, and Muin J. Khoury, Office of Genomics and Precision Public Health, Centers for Disease Control and Prevention

genomics, pharmacogenomics